

1 *Supplementary Information*

2  
3 **Bio-augmented Additive Manufacturing of Engineered**  
4 **Living Materials with Mechanical Enhancement and**  
5 **Resistance to Degradation**

6  
7 Gokce Altin-Yavuzarslan<sup>1</sup>, Sierra M. Brooks<sup>2</sup>, Shuo-FuYuan<sup>3</sup>, James O. Park<sup>3</sup>, Hal S.  
8 Alper<sup>2,3\*</sup>, Alshakim Nelson<sup>1,5\*</sup>

9  
10 <sup>1</sup>Molecular Engineering and Sciences Institute, University of Washington, Seattle, Washington  
11 98195, United States

12 <sup>2</sup>McKetta Department of Chemical Engineering, The University of Texas at Austin, Austin,  
13 TX, USA

14 <sup>3</sup>Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX,  
15 USA

16 <sup>4</sup>Department of Surgery, University of Washington, Seattle, Washington 98195, United States.

17 <sup>5</sup>Department of Chemistry, University of Washington, Box 351700, Seattle, WA, USA

18  
19 \*Corresponding Authors:

20 Prof. Hal S. Alper

21 Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX,  
22 USA

23 E-mail: halper@che.utexas.edu

24 Prof. Alshakim Nelson

25 Department of Chemistry, University of Washington, Box 351700, Seattle, WA, USA

26 E-mail: alshakim@uw.edu  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49	<b>This document includes:</b>
50	<b>Supporting experimental details, discussion, and references</b>
51	<b>Supplementary Table 1.</b> Name of 3D printed ELM samples.
52	<b>Supplementary Table 2.</b> Description of strains and plasmids
53	<b>Supplementary Table 3.</b> Primers and sequences
54	<b>Supplementary Table 4.</b> Rheological characterization.
55	<b>Supplementary Table 5.</b> Degree of swelling of SLA 3D printed samples
56	<b>Supplementary Fig 1.</b> Optical images of SLA 3D printed constructs.
57	<b>Supplementary Fig 2.</b> Optical images of ELM samples after culturing.
58	<b>Supplementary Fig 3.</b> Distribution of cells in SLA 3D printed ELM construct.
59	<b>Supplementary Fig 4.</b> Morphology of cells in SLA 3D printed ELM construct.
60	<b>Supplementary Fig 5.</b> Interaction of L-DOPA to BSA.
61	<b>Supplementary Fig 6.</b> Interaction of naringenin to BSA.
62	<b>Supplementary Fig 7.</b> Interaction of betaxanthins to BSA.
63	<b>Supplementary Fig 8.</b> Interaction of betaxanthins to Proteinase K
64	<b>Supplementary Fig 9.</b> Effect of betaxanthins on the secondary structure of Proteinase K.
65	<b>Supplementary Fig 10.</b> Optical images of BSA-PEGDA, ELM-SC-BXN and ELM-SC-WT
66	during degradation.
67	<b>Supplementary Fig 11.</b> The long-term viability of cells in ELM-SC-EY
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	

99

## 1. Supporting experimental details and discussion

100

101 The effect of PEGDA concentration and presence of microbial culture on printability  
102 of BSA-PEGDA conjugates were determined by characterization of rheological properties of  
103 resin formulations (Supplementary Table 3). In all formulations, resin viscosities were found  
104  $\leq 1$  Pa. s. After the addition of microbial culture media, resins were stirred for 30 min at 200  
105 rpm to maintain homogenous distribution of microorganism in the resin. It has been observed  
106 that when the 30 wt% BSA, 10 wt% PEGDA formulation was stirred for 30 min at 200 rpm  
107 the viscosity was changed 1.0 Pa. s (Entry 3, Supplementary Table 3) to 0.35 Pa. s (Entry 4,  
108 Supplementary Table 3). Therefore, it may be said that the viscosity reduction of Entry 5, Entry  
109 6, Entry 7, and Entry 8 was mainly caused by stirring step rather than the addition of  
110 microorganism or culture media to the resin formulation. According to the findings, Entry 1  
111 and Entry 2 required longer time, 47.5 s and 20 s, respectively, to reach the crossover point  
112 compared to other formulations (Supplementary Table 3). This longer time is not desirable to  
113 obtain 3D printed constructs in SLA 3D printers (Supplementary Fig. 1a). When PEGDA  
114 concentration was increased from 3 wt% to 10 wt%, the resin reached the crossover point at  
115 least 10 times faster (Entry 3, Supplementary Table 3). Presence of more PEGDA units in 30  
116 wt% BSA, 10 wt% PEGDA formulation led to the reaction of the acrylate groups with each  
117 other more easily. Therefore, this formulation provided faster photocuring rate and shorter time  
118 to achieve crossover point (Entry 3, Supplementary Table 3). 3D printed objects were  
119 successfully obtained with formulation 30 wt% BSA, 10 wt% PEGDA (Supplementary Fig.  
120 1b). In ELM formulations (Entry 6, and Entry 8, Supplementary Table 3,) both stirring step (30  
121 min at 200 rpm) and presence of microbial culture could affect the time to reach crossover  
122 point and rate of photocuring (Entry 6 and Entry 8, Supplementary Table 3). On the other hand,  
123 these changes did not affect the SLA.

124 To understand the effect of bioactive compounds produced from metabolically  
125 engineered cells on the BSA-PEGDA network, possible interactions between bioactive  
126 components and BSA were evaluated with UV-absorbance measurements. Supplementary Fig.  
127 5 represents the interaction of L-DOPA to BSA. The samples prepared as follows, BSA (0.5  
128 mg/ml in DI water), L-DOPA (0.5 mg/ml in DI water), BSA+L-DOPA (0.5 mg/ml for each  
129 component in DI water). Supplementary Fig. 6 shows the interaction of naringenin (NGN) to  
130 BSA. The samples prepared as follows, BSA (0.5 mg/ml in DI water). 100 mg/ml NGN stock  
131 solution was prepared in ethanol and diluted in water to 0.5 mg/ml. BSA+NGN sample  
132 contained 0.5 mg/ml for each component and prepared in DI water.

133 We observed that *in-situ* betaxanthins (BXN) production prevented microbial  
134 degradation, as both BSA-PEGDA and ELM-SC-BXN showed a similar trend in terms of mass  
135 change over 45 d. Two possible mechanisms of actions can be responsible to this resistance:  
136 binding of BXN to degradation enzymes such as proteinase or binding of BXN to BSA.<sup>[1-3]</sup> We  
137 selected ProK as a model enzyme to examine the binding of BXN to microbial enzymes. The  
138 binding of BXN to BSA and ProK was confirmed by UV-vis absorbance and CD-spectroscopy.  
139 The absorbance of both proteins, as well as BXN, was changed after they interact with each  
140 other Supplementary Fig. 7 and Supplementary Fig. 8. In addition, the binding of BXN to BSA  
141 resulted in the loss of the  $\alpha$ -helical structure of BSA. The characteristic spectrum of  $\alpha$ -helix  
142 motif in the negative region at between 222 to 208 nm disappeared in the presence of BXN (  
143 Fig. 5b). Similarly, conformational changes were observed in ProK after the binding of BXN  
144 to this protein (Supplementary Fig. 0). The weak negative peak between 230 to 220 nm belongs  
145 to  $\beta$ -turns<sup>[2]</sup> and the  $\beta$ -sheet motif in ProK<sup>[2]</sup> was identified (Supplementary Fig 12). In the  
146 presence of BXN, the characteristic CD spectra of ProK were completely changed. BXN alter  
147 the structural motifs, both  $\beta$ -sheets, and  $\beta$ -turns, of ProK.

148

149 **Literature Cited**

150

151 [1] S. Paudyal, G. Sigdel, S. K. Shah, S. K. Sharma, J. D. Grubb, M. Micic, L. Caseli, R. M.  
152 Leblanc, *J Colloid Interface Sci* **2022**, *616*, 701-708.

153 [2] J. Liu, H. Yong, X. Yao, H. Hu, D. Yun, L. Xiao, *RSC Adv* **2019**, *9*, 35825-35840.

154 [3] M. I. Khan, P. Giridhar, *Phytochemistry* **2015**, *117*, 267-295.

155 [4] S. Zhou, S. F. Yuan, P. H. Nair, H. S. Alper, Y. Deng, J. Zhou, *Metab Eng* **2021**, *67*, 41-  
156 52.

157 [5] T. G. Johnston, S. F. Yuan, J. M. Wagner, X. Yi, A. Saha, P. Smith, A. Nelson, H. S. Alper,  
158 *Nat Commun* **2020**, *11*, 1-11.

159

160 **Supplementary Table 1.** Name of 3D printed ELM samples, the microorganisms that each  
161 sample contains, and the bioactive compound that is produced from each microorganism.

Sample	Microorganisms	Bioactive compound
ELM-SC-WT	Wild type <i>S. cerevisiae</i>	-
ELM-SC-WT	Wild type <i>E. coli</i>	-
ELM-SC-BXN	<i>S. cerevisiae</i> BY4741	Betaxanthin
ELM-EC-LDOPA	<i>E. coli</i> BL0430D	L-DOPA
ELM-EC-NGN	<i>E. coli</i> BL21(DE3)	Naringenin

162

163

**Supplementary Table 2.** Description of strains and plasmids

Strain/plasmid	Description	Source
<i>E. coli</i> strains		
BL21(DE3)	<i>E. coli</i> str. B F <sup>-</sup> ompT gal dcm lon hsdSB( <sub>rb</sub> <sup>-</sup> mB <sup>-</sup> ) λ (DE3 [lacI lacUV5- T7p07 ind1 sam7 nin5]) [malB <sup>+</sup> ] <sub>K-12</sub> (λ <sup>S</sup> )	New England Biolabs
<i>E. coli</i> BL21(DE3) Mut-17	[BL21(DE3)]: pETM-PUTRtrxA-TAL-PUTRtalB-4CL, pCDM-PssrA-UTRrpsT-CHS-PUTRglpD-CHI, pACM-PfdeR-mut-FdeR-PfdeA-mut-acpH-asacpT-asacpS, and pRSM-PcspA-mut-PadR-acs-ACC (KanR, AmpR, SpcR, CmR)	Reference <sup>4</sup>
eBL0430D	[ <i>E. coli</i> BL21(DE3)] ΔtyrR , pET28-pYIBN-aroG(fbr)-B30rbs-tyrA(fbr)-tRRNC; KanR , pCDF-pLPP-B30rbs-hpaB-hpaC-T7t; KanR; SpcR	Reference <sup>5</sup>
<i>S. cerevisiae</i> strains		
BY4741	MATα SUC2 gal2 mal2 mel flo1 flo8-1 hap1 ho bio1 bio6 his3Δ1 leu2Δ0 met15Δ0 ura3Δ0	American Type Culture Collection (ATCC)
BY01	<i>S. Cerevisiae</i> BY4741: ura3:pCCW12-MjDOD(T261N; ACC to AAC)-pTDH3-CYP76AD5 -tPRM9 (URA3integration with Leu2 marker)	This Study
Plasmids		
pET28-pYIBN-aroG(fbr)-B30rbs-tyrA(fbr)-tRRNC. KanR	For L-DOPA production	Reference <sup>5</sup>
pCDF-pLPP-B30rbshpaB-hpaC-T7t. SpcR	For L-DOPA production	Reference <sup>5</sup>
pETM-PUTRtrxA-TAL-PUTRtalB-4CL	For Naringenin production	Reference <sup>4</sup>
pCDM-PssrA-UTRrpsT-CHS-PUTRglpD-CHI	For Naringenin production	Reference <sup>4</sup>
pACM-PfdeR-mut-FdeR-PfdeA-mut-acpH-asacpT-asacpS	For Naringenin production	Reference <sup>4</sup>
pRSM-PcspA-mut-PadR-acs-ACC	For Naringenin production	Reference <sup>4</sup>

167 **Supplementary Table 3. Primers and sequences**

Primer	Sequence (5'-3')
P1	GTGGTTTCAGGGTCCATAAAGCgagctcCTGAACTGGCCGATAATTGC
P2	gatgcgtaaggagaaaataccgcatcaggTAGGTTGTCTGTGCCCATAC
P3	CCTGATGCGGTATTTTCTCCTTACG
P4	GAGCTCGCTTTATGGACCCTG
P5	GAAGGATAAGTTTTGACCATCAAAG
P6	GGTGAAGTTGTAGGTAGAGTAACC

168  
169

170 **Supplementary Table 4.** Effect of PEGDA concentration and microbial culture media on  
 171 rheological properties and SLA 3D printability of BSA-PEGDA conjugates.

Entry	BSA wt. %	PEGDA wt. %	Microbial Culture Media	Viscosity (Pa s)	G' rate change (Pa/s)	Crossover point (s)	Printability
1	30	3	-	0.17	0.003	47.5	No
2	30	5	-	0.40	70.45	20.0	No
3	30	10	-	1.00	2884.1	4.0	Yes
4*	30	10	-	0.35	-	-	Yes
5	30	10	LB	0.27	3535.07	10.0	Yes
6	30	10	<i>E. coli</i>	0.13	1238.82	13.5	Yes
7	30	10	YPD	0.35	1088.56	8.0	Yes
8	30	10	<i>S. cerevisiae</i>	0.30	1620.55	12.0	Yes

172 \* Entry 4 was stirred for 30 min before measurement similar to Entry 5-8. These samples  
 173 were stirred after the addition of microbial culture and/or culture media to provide the  
 174 homogenous distribution of added compounds to resin formulation.  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207




208  
209  
210

**Supplementary Table 5.** Degree of swelling of SLA 3D printed samples. (Samples were prepared in triplicate, ( $\pm$  s.d).

Sample	Degree of Swelling (q)
BSA-PEGDA in LB media	$1.56 \pm 0.05$
ELM-EC-LDOPA	$1.34 \pm 0.01$
ELM-EC-WT	$1.56 \pm 0.07$
BSA-PEGDA+L-DOPA	$1.33 \pm 0.17$
ELM-EC-NGN	$2.70 \pm 0.4$
BSA-PEGDA+NGN	$1.10 \pm 0.01$
BSA-PEGDA in YPD media	$1.63 \pm 0.03$
ELM-SC-BXN	$1.61 \pm 0.07$
ELM-SC-WT	$1.89 \pm 0.01$


211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230



**Supplementary Figure 1.** Optical images of SLA 3D printed constructs. (a) Formulation of 30 wt% BSA with 5 wt% PEGDA (Entry 2, Table S2), unsuccessful printing, delamination was observed. (b) Formulation of 30 wt% BSA with 10 wt% PEGDA (Entry 3, Table S2), printing was successfully completed.


231

232




**Supplementary Figure 2.** Optical images of ELM samples after culturing. (a) ELM-SC-BXN cultured in YPD for 1 d, (b) ELM-SC-BXN in YPD, cultured for 1 d, (c) ELM-EC-LDOPA in vitamin C supplemented LB media cultured for 1 d, (d) ELM-EC-LDOPA in LB media cultured for 1 d.

234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252




**Supplementary Figure 3.** Distribution of cells in SLA 3D printed ELM construct. (a), Schematic illustration of ELM-SC-BXN sample and location of each section that was imaged in the scanning electron microscope (SEM), (b) SEM images of *S. cerevisiae* in ELM-SC-BXN, images were taken at 500x magnification.




**Supplementary Figure 4.** Morphology of cells in 3D printed ELMs. (a) SEM images of *E. coli* in 3D printed ELM-EC-LDOPA constructs at different magnifications; 1000X magnification (scale bar 20 micron), 5000X (scale bar 5 micron), 20000X (scale bar 1 micron), (b) SEM images of *S. cerevisiae* in 3D printed ELM-SC-BXN constructs at different magnifications; 1500X magnification (scale bar 20 micron), 2500X (scale bar 10 micron), 7000X (scale bar 2 micron).

257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273



**Supplementary Figure 5.** Interaction of L-DOPA to BSA. UV-absorption spectra of BSA, L-DOPA, sum of individual spectra of BSA and L-DOPA, and spectra of BSA+L-DOPA mixture.


274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285



**Supplementary Figure 6.** Interaction of naringenin (NGN) to BSA. UV-absorption spectra of BSA, NGN, sum of individual spectra of BSA and NGN, and spectra of BSA+NGN mixture.

287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314


315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364



**Supplementary Figure 7.** Interaction of betaxanthins (BXN) to BSA. UV-absorption spectra of BSA, BXN, sum of individual spectra of BSA and BXN, and spectra of BSA+BXN mixture.




365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414




**Supplementary Figure 8.** Interaction of betaxanthins (BXN) to Proteinase K (ProK). UV-absorption spectra of ProK, BXN, sum of individual spectra of ProK and BXN, and spectra of ProK+BXN mixture.

415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464




**Supplementary Figure 9.** Effect of betaxanthins (BXN) on the secondary structure of Proteinase K (ProK). CD spectra of ProK and CD spectra of ProK with the presence of BXN (ProK+BXN).

465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514



**Supplementary Figure 10.** Degradation of BSA-PEGDA, ELM-SC-WT and ELM-SC-BXN samples over 30 d.

515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535



**Supplementary Figure 11.** The long-term viability of cells in ELM-SC-BXN (samples collected on day 40).